OrbiMed’s Tricida, Inc. Common Stock TCDA Stock Holding History

OrbiMed’s Portfolio TCDA Stock Details TCDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,280,947	Closed	-$108K	–	136
2022 Q3	$108K	Hold	10,280,947	–	–	2%	12
2022 Q2	$99.5K	Hold	10,280,947	–	–	1.8%	20
2022 Q1	$84.5M	Hold	10,280,947	–	–	1.37%	25
2021 Q4	$98.3M	Buy	10,280,947 +666,667	+7%	+$4.3M	1.26%	29
2021 Q3	$44.6M	Hold	9,614,280	–	–	0.49%	57
2021 Q2	$41.5M	Hold	9,614,280	–	–	0.42%	64
2021 Q1	$50.9M	Hold	9,614,280	–	–	0.48%	58
2020 Q4	$67.8M	Hold	9,614,280	–	–	0.59%	48
2020 Q3	$87.1M	Hold	9,614,280	–	–	1.09%	27
2020 Q2	$264M	Hold	9,614,280	–	–	3.72%	2
2020 Q1	$212M	Hold	9,614,280	–	–	3.55%	2
2019 Q4	$363M	Sell	9,614,280 -1,500,000	-13%	-$55.9M	5.18%	3
2019 Q3	$343M	Hold	11,114,280	–	–	6.51%	2
2019 Q2	$439M	Buy	11,114,280 +225,000	+2%	+$7.91M	6.79%	2
2019 Q1	$421M	Hold	10,889,280	–	–	6.51%	2
2018 Q4	$257M	Hold	10,889,280	–	–	4.75%	1
2018 Q3	$333M	Hold	10,889,280	–	–	4.01%	2
2018 Q2	$326M	Buy	+10,889,280	New	+$304M	3.88%	3

Other funds holding TCDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed's TCDA Position: Q4 2022 in Review

OrbiMed sold out of Tricida, Inc. Common Stock (TCDA) in Q4 2022, closing a stake of 10,280,947 shares — an estimated $108K sold.

OrbiMed first reported a position in TCDA in Q2 2018 and held it in 18 quarters. The position peaked at $439M in Q2 2019. 70 funds tracked by Wall St. Rank hold TCDA as of Q4 2022.

OrbiMed reported no remaining Tricida, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
OrbiMed sold 10,280,947 Tricida, Inc. Common Stock shares in Q4 2022, an estimated $108K.
OrbiMed first reported a position in Tricida, Inc. Common Stock in Q2 2018 and held it in 18 quarters.
OrbiMed's Tricida, Inc. Common Stock position peaked at $439M in Q2 2019.
70 funds tracked by Wall St. Rank held Tricida, Inc. Common Stock as of Q4 2022.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.